A bipartisan Senate bill introduced this month would direct the National Institutes of Health to support a clinical research network built specifically to speed trials of new antibiotics, addressing a bottleneck that has left resistant infections outpacing the drugs available to treat them.
The Stop Superbugs Act, introduced by Sens. Maggie Hassan of New Hampshire and Roger Marshall of Kansas, would authorize the NIH's Antimicrobial Resistance Leadership Group to facilitate clinical trials for new antibiotics. Marshall, a physician, framed the stakes plainly: "We've made incredible progress because of antibiotics, but they're only valuable if they still work." He added that the bill helps strengthen the research network and clinical trials needed to speed new treatments from the lab to the bedside.
The bill was introduced alongside a Joint Economic Committee report estimating that multidrug-resistant infections in hospital patients cost the U.S. health care system $5.7 billion annually, a figure the report notes is likely an underestimate once follow-up care, patient out-of-pocket costs, lost work time and diminished productivity are counted.
The Trial Bottleneck the Bill Targets
Antibiotic trials are unusually difficult to run, and the difficulty is structural rather than a matter of insufficient interest.
Patients with serious resistant infections need treatment immediately. Confirming which organism is causing an infection, and which drugs it resists, often takes longer than the window in which treatment must begin. That timing conflict makes enrolling the right patients into the right trial arm genuinely hard.
Resistant infections are also scattered. A hospital may see a handful of carbapenem-resistant cases in a year, which means a trial needs many sites to accumulate enough patients, and each site requires setup, training, and regulatory approval before enrolling anyone.
The bill's stated objectives map onto these problems directly: rapid recruitment of clinical trial participants, community-based recruitment outreach, pairing new antibiotics with better diagnostics during trials, and development of patient-reported outcomes.
The diagnostics element is the least obvious and among the most important. Faster identification of the organism and its resistance profile would let clinicians match patients to the right trial and, later, to the right drug in ordinary practice.
The Scale of the Clinical Problem
"Nearly 3 million Americans get sick each year with an infection that cannot be treated with the routine antibiotics that we have today," Hassan said. "Doctors who are treating patients with a resistant infection often have to try multiple antibiotics, and in some cases, no treatment options exist." CDC has estimated more than 2.8 million drug-resistant infections annually in the United States, causing roughly 35,000 deaths.
Hassan also framed the issue as a matter of national security, warning that if the United States does not keep up with the science and innovation coming from countries like China, it risks becoming reliant on critical new medications available only abroad.
The pipeline has not kept pace. Antibiotic innovation has been largely incremental for decades, focused on later-generation and combination drugs built on existing chemical scaffolds. Truly novel therapies with new mechanisms of action have entered early trials at a rate below what the problem demands.
The hardest targets are gram-negative bacteria, which are difficult to treat because of robust cell wall barriers that block many antibiotics from entering and efflux pumps that eject those that do. Carbapenem-resistant Enterobacterales including E. coli and Klebsiella, along with resistant Acinetobacter baumannii and Pseudomonas aeruginosa, sit at the top of the concern list.
Progress does occur. MedicalDaily reported earlier this year on the FDA approval of a new intravenous antibiotic combination for complicated urinary tract infections caused by drug-resistant gram-negative pathogens, and on laboratory work restoring the potency of vancomycin. Individual advances do not close the gap on their own.
The Piece This Legislation Does Not Address
Trial infrastructure is one of two acknowledged problems in antibiotic development. The other is economics, and this bill does not touch it.
New antibiotics face an unusual commercial situation. When a genuinely novel drug reaches the market, good stewardship dictates holding it in reserve for infections that nothing else treats. Low sales volume is the clinically correct outcome and the commercially ruinous one. Several companies that brought new antibiotics to market in recent years have gone bankrupt or been sold.
Neither the Antimicrobial Resistance Leadership Group nor the federal government is positioned to bring antibiotics to market, and infectious disease specialists have argued that separate financing mechanisms are needed to sustain private investment.
That is the aim of a different bill. The PASTEUR Act would create a subscription program in which federal reimbursement for novel antibiotics is delinked from sales volume, providing predictable returns that align with appropriate use. It was first introduced in 2020 and has yet to be adopted. A third measure, the SUPER BUGS Act, addresses international coordination.
The approaches are complementary rather than competing. One addresses whether trials can be run efficiently; the other addresses whether a company that succeeds can stay solvent.
The Legislative Outlook and What Patients Can Do
The bill is one of several in Congress targeting antibiotic resistance, and its practical significance depends on whether it advances and is funded.
None of this changes anything a patient can act on this week, and no legislation will produce a new antibiotic quickly. Even under ideal conditions, moving a candidate from early trials to approval takes years.
What individuals influence is the rate at which resistance develops. Taking antibiotics only when prescribed for a bacterial infection, completing the course as directed, not saving leftover pills or using someone else's prescription, and accepting a clinician's judgment when antibiotics are not indicated for a viral illness all matter at population scale. Staying current on vaccines that prevent bacterial infections, including pneumococcal vaccines, reduces antibiotic need in the first place.
Patients hospitalized with a serious infection can reasonably ask whether cultures have been sent, whether the antibiotic can be narrowed once results return, and whether a clinical trial is available at that facility.
Key Questions Answered
What would the bill do? Authorize the NIH's Antimicrobial Resistance Leadership Group to facilitate clinical trials for new antibiotics, with objectives including rapid participant recruitment, community-based outreach, pairing new drugs with better diagnostics, and developing patient-reported outcomes.
Who introduced it? Sens. Maggie Hassan of New Hampshire and Roger Marshall of Kansas, in a bipartisan pairing.
Why are antibiotic trials so hard to run? Patients with serious resistant infections need treatment before lab results confirm which organism and which resistance pattern is involved. Resistant cases are also scattered across many hospitals, requiring large multi-site networks.
How large is the problem? CDC has estimated more than 2.8 million drug-resistant infections annually in the United States, causing roughly 35,000 deaths. A congressional report puts the hospital cost of multidrug-resistant infections at $5.7 billion a year, likely an underestimate.
Does this bill fix the antibiotic pipeline? No. It addresses trial infrastructure, not economics. New antibiotics are held in reserve for good clinical reasons, which suppresses sales and has driven developers into bankruptcy. A separate bill, the PASTEUR Act, targets that problem and has not been adopted since first appearing in 2020.
How soon could this produce a new drug? Not soon. Moving an antibiotic candidate from early trials through approval takes years even under favorable conditions.
What can individuals do about resistance? Take antibiotics only when prescribed for a bacterial infection, complete the course, never use leftover or someone else's pills, accept when a clinician says antibiotics are not indicated, and stay current on vaccines that prevent bacterial infections.
